Precipio, Inc.

NasdaqCM PRPO

Precipio, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024

Precipio, Inc. Cash and Short-Term Investments is NA for the quarter ending September 30, 2024. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Precipio, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 5.14 M, a -61.10% change year over year.
Precipio, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 13.22 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: PRPO

Precipio, Inc.

CEO	Mr. Ilan Danieli
IPO Date	June 30, 2017
Location	United States
Headquarters	4 Science Park
Employees	51
Sector	Healthcare
Industries Biotechnology

Description

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

Key trends

Past 5 years